Sjuts Dustin S 4
4 · Revance Therapeutics, Inc. · Filed Dec 16, 2022
Insider Transaction Report
Form 4
Sjuts Dustin S
Chief Commercial Officer
Transactions
- Tax Payment
Common Stock
2022-12-15$21.50/sh−2,916$62,694→ 95,207 total
Footnotes (1)
- [F1]Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 11,973 shares. The RSA vests in three equal annual installments from December 15, 2021, subject to Mr. Sjuts' Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.